Summary
Eli Lilly and Company (LLY) has announced a significant leadership change, appointing Lucas Montarce as its new Executive Vice President and Chief Financial Officer, effective September 9, 2024. This appointment follows an extensive search and reflects Mr. Montarce's long tenure and diverse financial leadership experience within Lilly, including his most recent role as president and general manager for the Spain, Portugal, and Greece hub, and prior experience as group vice president, controller, and CFO of Lilly Research Laboratories. Investors should note that this change in CFO is typically a key event, and Mr. Montarce's compensation package includes an annualized base salary of $1,000,000 and an annualized target bonus of $1,000,000. The filing also confirms that Mr. Montarce's appointment was made without any pre-existing arrangements with other individuals, and he has no familial ties to current directors or executive officers, nor is he involved in any related-party transactions requiring disclosure under Regulation S-K. The company has attached a press release detailing this announcement as an exhibit to the 8-K filing. This transition at the CFO level is an important factor for investors to monitor as it can impact financial strategy and reporting going forward.
Key Highlights
- 1Lucas Montarce appointed as Executive Vice President and Chief Financial Officer (CFO), effective September 9, 2024.
- 2Mr. Montarce has a deep history with Eli Lilly, joining in 2001 and holding various senior finance leadership positions.
- 3Most recent role for Mr. Montarce was President and General Manager for the Spain, Portugal, and Greece hub.
- 4Prior to that, he served as Group Vice President, Controller, and CFO of Lilly Research Laboratories.
- 5Mr. Montarce's compensation includes an annualized base salary of $1,000,000 and an annualized target bonus of $1,000,000.
- 6The appointment was made following an internal and external search process.
- 7The company confirms no undisclosed arrangements or related-party transactions concerning Mr. Montarce's appointment.